Bishkek, July 28, 2021 . / Kabar /. 25 thousand doses of QazVac Kazakh coronavirus vaccine arrived in Kyrgyzstan on July 28 as a humanitarian aid, the press service of the Kyrgyz Ministry of Health said.
The handover ceremony was held with the participation of Minister of Health Alymkadyr Beishenaliev, Kazakh Ambassador to Kyrgyzstan Rapil Zhoshybayev and representatives of the Research Institute for Biological Safety Problems of the Kazakh Ministry of Education and Science, which developed the vaccine.
"The delivery of the first batch of the Kazakh vaccine was organized by the government of Kazakhstan on assignment of our president Kassym-Jomart Tokayev. The agreement to supply vaccines was reached as a result of talks between presidents of the two countries. This once again confirms the good-neighborly and friendly relations between our countries," said Ambassador Rapil Zhoshybayev.
During the meeting, Kyrgyzstan’s Health Minister Beishenaliyev expressed gratitude to the Kazakh Government and the Embassy of Kazakhstan for supporting the high-level Kyrgyz-Kazakh partnership and commitment to the elimination of COVID-19.
"Today we are receiving another shipment of humanitarian aid from the Government of Kazakhstan in the form of QazVac vaccine in the amount of 25 thousand doses. That's 12,500 people protected from a severe form of COVID-19. I express my gratitude for the help and hope for further development of friendly relations between our countries", he added.
One of the developers of the QazVac vaccine Yergali Abduraimov, the deputy director general of the Research Institute for Biological Safety Problems of the Kazakh Ministry of Education and Science noted that this vaccine is recommended for all persons over 18 years old who wish to be vaccinated. The recommended interval between the 1st and 2nd doses is 21 days.
"Over 300 thousand Kazakhstanis have been vaccinated to date and no serious side effects have been recorded. The technology uses those components which are approved by WHO, it is a standard technology. Not a single case of undesirable effects has been identified to date," Abduraimov noted.
QazCovid-in, commercially known as QazVac, is a COVID-19 vaccine developed by the Research Institute for Biological Safety Problems in Kazakhstan. QazCoVac-P is a second COVID-19 vaccine developed by the Kazakh Biosafety Research Institute and in clinical trials.
The administration of the vaccine for the general population began at the end of April 2021. The Research Institute Kunsulu Zakarya's Director General's justification is that the trial is almost 50% completed and "people who have received [the] vaccine feel well; there have been no side-effects and the effectiveness of the vaccine is high".
Comments
Post Comment